BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amorfix Life Sciences Ltd. Provides Corporate Update on Regulatory Processes and Manufacturing for vCJD Diagnostic


9/9/2008 6:40:30 AM

TORONTO, Sept. 9 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced an update on the regulatory process in the European Union (EU) and manufacturing for vCJD blood screening tests.

The EU Commission's In Vitro Diagnostics Technical Group and government representatives from EU member countries met in Brussels earlier this summer to consider expert scientific information in determining the process for regulating vCJD tests. Amorfix attended as an industry expert and presented the European Diagnostic Manufacturer's Association's (EDMA) position on the standards that should be established for a first blood screening test for vCJD. The EDMA proposal was broadly circulated for comments to be reviewed at the next Commission meeting planned for early October.

"Amorfix and EDMA are taking a leadership role in advising on the scientific and practical considerations involved in regulating vCJD diagnostic blood screening assays," said Dr. George Adams, President & CEO, Amorfix. "We are encouraged by the broad EU member state support for the establishment of regulations for this test."

Amorfix has now established ISO 13485:2003 certification at its facility in Mississauga, Ontario and in its new Prion Containment Laboratory which has also been certified by the Canadian Food Inspection Agency and the Public Health Agency of Canada. This laboratory is required for the development of prion-related assays and for the quality control and release of test kits. Real-time testing of the EP-vCJD(TM) Blood Screening Assay diagnostic kit has now confirmed a shelf life of 12 months for all critical reagents.

"Amorfix's ISO quality systems have been established for manufacturing and distribution of the vCJD blood screening test," said Milan Striez, Director of Operations at Amorfix. "The on-going shelf-life testing continues to demonstrate stability of the test kits and we are confident that the stability will meet the standards of our prospective customers."

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF - News) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information

Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899, george.adams@amorfix.com James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899, james.parsons@amorfix.com

Source: Amorfix Life Sciences Ltd.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES